The commencement of sea trials for the nuclear-powered aircraft carrier USS John F. Kennedy coincides with the 140th anniversary of its builder, Newport News Shipbuilding, underscoring Huntington Ingalls Industries' entrenched role in U.S. naval defense and its long-term investment profile.
Since its spin-off from GE Aerospace, GE Vernova's stock has soared over 400%. While its position in gas, wind, and next-gen nuclear power is formidable, sky-high valuations give even growth investors pause.
Eli Lilly commits $85 million upfront and over $1.8 billion in potential milestones to partner with Repertoire Immune Medicines, aiming to develop a new class of 'tolerizing' therapies that reset the immune system without broad suppression.
Sanofi reports a pivotal Phase 3 win for its investigational therapy venglustat in a rare neurological disorder, alongside positive EU regulatory news for Rezurock and progress for amlitelimab, signaling a strategic shift toward high-value specialty medicines.
Egypt reopened the Rafah border crossing on Tuesday, allowing the first medical evacuation from Gaza since its latest closure. A critically wounded Palestinian patient was transferred to an Egyptian hospital, amid ongoing hostilities in the Strip.
H.C. Wainwright maintains a Buy rating on Lexeo Therapeutics but slashes its price target, citing persistent market doubts over the company's PKP2 cardiomyopathy program despite encouraging early clinical results.
Barclays initiates coverage of 4D Molecular Therapeutics with an Overweight rating and a $33 price target, citing a favorable industry backdrop with potential M&A tailwinds and shifting focus away from drug pricing pressures. The gene therapy developer also outlined key clinical milestones expected through 2026.
H.C. Wainwright and Chardan Capital upgrade Korro Bio (KRRO) to Buy, citing the independent potential of its RNA-editing asset KRRO-121 and strong preclinical data as key catalysts.
Following a price target adjustment by Leerink Partners, Kura Oncology (KURA) is drawing investor focus to its 2026 clinical milestones and commercial strategy for its newly launched AML drug, ziftomenib.
The Apis Flagship Fund reported robust quarterly and annual gains for 2025, significantly beating global benchmarks. While highlighting its performance drivers, the fund's investor letter also discussed its position on gene therapy firm uniQure (QURE).
Apis Capital's flagship fund, which surged 55% in 2025, spotlights clinical-stage biotech Celcuity in its latest investor letter, citing the company's novel platform for matching cancer patients with targeted therapies.
Pakistan has announced it will not play its scheduled T20 World Cup match against India, a decision linked by officials to recent deadly attacks in Balochistan and broader geopolitical disputes involving Bangladesh's tournament exclusion.
The European Union has firmly rejected Iran's retaliatory designation of EU member states' armed forces as 'terrorist groups,' a move that came days after the bloc formally listed Iran's Islamic Revolutionary Guard Corps (IRGC) as a terrorist organization, escalating a diplomatic tit-for-tat.
KTM's preliminary 2025 financial results reveal a steep decline in revenue and sales, casting doubt on the efficacy of recent restructuring efforts and raising questions about the brand's near-term recovery trajectory.
The pharmaceutical giant's final major U.S. facility will rise in Pennsylvania's historic Lehigh Valley, aiming to produce its promising triple-hormone drug retatrutide and bolster domestic supply chains for blockbuster obesity treatments.
Senior U.S. envoy Steve Witkoff is set to arrive in Jerusalem for meetings with Prime Minister Netanyahu and military leaders, as Washington seeks to navigate escalating regional tensions with Iran and advance efforts to end the Gaza conflict.
A hawkish Fed nominee and geopolitical tensions trigger a broad market sell-off, with one analyst forecasting an 87% collapse in Bitcoin from current levels.
A sharp 16% weekly decline in enGene Holdings' share price puts significant pressure on its largest shareholder group—private equity firms controlling nearly half the company—raising questions about strategy and future direction amid broader market volatility.
A bus carrying Ukrainian miners home from their shift was struck by Russian drones in a coordinated attack, leaving at least 15 dead and 7 wounded. The assault, condemned as an act of terrorism, marks one of the deadliest single incidents for the energy company DTEK since the invasion began.
While stocks priced between $10 and $50 can appear to offer an attractive balance of accessibility and maturity, their low price tags can sometimes mask underlying vulnerabilities. We examine three such companies where caution may be prudent.
